<DOC>
	<DOCNO>NCT02790775</DOCNO>
	<brief_summary>In double blind clinical trial , 1000 patient suffer diabetic macular edema , age-related macular degeneration , neovascularization due proliferative diabetic retinopathy cystoid macular edema secondary retinal vascular occlusion include . Those history Ocular pain prior procedure , contraindication Intravitreal Bevacizumab Injection ( IVI ) , history kind anterior segment condition could affect pain sensation , history use systemic analgesic sedative medication , history previous eye surgery cataract , glaucoma , uveitis bullous keratopathy poor cooperation use visual analogue scale ( VAS ) exclude study . Before start treatment patient undergo complete ophthalmic exam , best-corrected visual acuity ( BCVA ) check macular thickness measurement use optical coherence tomography ( OCT ) . Patients randomly assign group .Each participant receive one injection one eye study . Pain measure subjective grade Visual Analog Scale ( VAS ) immediately IVI . BCVA OCT would check month one .</brief_summary>
	<brief_title>Pain Visual Outcome Intravitreal Bevacizumab Injection</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>diabetic macular edema , agerelated macular degeneration , neovascularization due proliferative diabetic retinopathy cystoid macular edema secondary retinal vascular occlusion history Ocular pain prior procedure , contraindication Intravitreal Bevacizumab Injection ( IVI ) , history kind anterior segment condition could affect pain sensation , history use systemic analgesic sedative medication , history previous eye surgery cataract , glaucoma , uveitis bullous keratopathy poor cooperation use visual analogue scale ( VAS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>